National Natural Science Foundation of China(Nos. 81770190, 81970161);National Key Research and Development Program of China(Nos. 2017YFA105500,2017YFA105504);Research and Development Program in Key Areas of Guangdong Province(No. 2019B020236004);Natural Science Foundation of Guangdong Province(No. 2019A1515011924);Project of the Zhujiang Science and Technology Star of Guangzhou City(No. 201806010029);Key Clinical Research Project of Southern Medical University(No. LC2016ZD009)。
Background: Compared with human leukocyte antigen (HLA)-matched sibling donor (MSD) transplantation, it remains unclear whether haploidentical donor (HID) transplantation has a superior graft-versus-leukemia (GVL) eff...
supported by grants from the National Key Research and Development Program of China(2017YFA0104500);the Beijing Municipal Science and Technology Commission(Z181100009618032);the National Natural Science Foundation of China(Grant No.81621001,81530046,81770189,81670186,81870141 and 82070185);CAMS Innovation Fund for Medical Sciences(CIFMS)(grant number:2019-I2M-5-034);the Peking University Clinical Scientist Program(BMU2019LCKXJ003).
Haploidentical stem cell transplantation(haplo-SCT)achieves superior or at least comparable clinical outcomes to HLA-matched sibling donor transplantation(MSDT)in treating hematological malignancies.To define the unde...
Aim Allogeneic hematopoietic stem cell transplantation (HSCT) has curable potential for hematopoietic malignancies through graft-versus-leukemia (GVL) effects but is often associated with life-threatening graft-ve...
ThisstudywassupportedbytheNationalNatureScienceFoundationofChina (NO 3 9970 70 6)
Background We distinguished graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) effects and to investigate the distribution of T-cell receptor (TCR) Vβ gene repertoire in individuals with leukemia befor...